leadf
logo-loader
viewClinigen Group PLC

Clinigen Group PLC boss excited about perampanel South Africa approval

Chief executive of Clinigen Group PLC (LON:CLIN) Shaun Chilton explains the significance of the firm's approval for perampanel, a treatment for seizures associated with epilepsy.
"This is the first new anti-epileptic to be approved in South Africa for quite a number of years," he told Proactive's Charlotte Kan, adding that epilepsy affects one in every 100 people in the country.

Quick facts: Clinigen Group PLC

Price: 640.5 GBX

AIM:CLIN
Market: AIM
Market Cap: £852.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Benchmark Holdings' present at the Proactive One2One Virtual Forum

Benchmark Holdings' (LON:BMK) Trond Williksen, CEO & Septime Maguire, CFO pitch to investors at the Proactive One2One virtual forum.  Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability. We bring together biology and technology, to...

22 hours, 21 minutes ago

2 min read